ArticleEuropean journal of nuclear medicine and molecular imaging2026
Systemic brain-body metabolic coupling patterns in amyotrophic lateral sclerosis: a whole-body [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder involving both central and peripheral systems. Its marked heterogeneity and variable prognosis suggest pathophysiology beyond motor neuron degeneration. This study aimed to map brain–body metabolic networks using whole-body [18F]FDG PET/CT, characterize systemic remodeling, and to identify clinically meaningful brain-organ coupling axes and peripheral prognostic markers (lung, small intestine, cervical cord, intrinsic spinal muscles), providing imaging candidates for phenotype-informed stratification and hypothesis generation for future multimodal studies.
methodsWe enrolled 121 ALS patients and 83 controls who underwent whole-body [18F]FDG PET/CT. Standardized uptake value ratios (SUVr), mean Standardized uptake value (SUVmean), and maximum Standardized uptake value (SUVmax) were extracted from brain regions and 11 peripheral organs. Interregional metabolic correlation networks were constructed, and subgroup analyses were performed according to King's stage, progression rate, site of onset, genetic mutations, and non-motor symptoms (NMS). Associations between metabolic alterations and survival were examined using longitudinal follow-up.
resultsCompared to controls, ALS patients exhibited hypometabolism in the frontal lobe and motor cortex, but hypermetabolism in the posterior cingulate and parahippocampal regions. Peripheral alterations included increased metabolism in the liver, spleen, thoracic spinal cord, and spinal muscles, as well as reduced metabolism in the lungs. Brain–body network analysis revealed that advanced King's stages were associated with strengthened brain–heart metabolic coupling. Rapid progression subtypes exhibited enhanced brain-spinal cord coupling and concomitant hypometabolism in the small intestine and thoracic spinal cord. Bulbar-onset ALS demonstrated increased cardiac metabolism but reduced brain–heart coupling. Patients with genetic mutations or NMS exhibited disrupted brain–body co-variation. In unadjusted analyses, survival analysis demonstrated that lung and intestinal hypometabolism and hypermetabolism in the intrinsic spinal muscles and cervical spinal cord were significantly associated with poor prognosis; after Benjamini–Hochberg false discovery rate correction, only intrinsic spinal muscle SUVr remained significant.
conclusionALS is a systemic disorder characterized by widespread remodeling of brain–body metabolic networks. Whole-body [18F]FDG PET/CT enables the detection of multi-organ metabolic abnormalities and uncovers inter-system coupling mechanisms, offering biomarkers for stratification, prognosis prediction, and individualized management.
Indexed as
Identifiers
41588209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.